CN108658958A - A kind of amide derivatives and its application as endothelin-receptor antagonists - Google Patents

A kind of amide derivatives and its application as endothelin-receptor antagonists Download PDF

Info

Publication number
CN108658958A
CN108658958A CN201810560070.0A CN201810560070A CN108658958A CN 108658958 A CN108658958 A CN 108658958A CN 201810560070 A CN201810560070 A CN 201810560070A CN 108658958 A CN108658958 A CN 108658958A
Authority
CN
China
Prior art keywords
endothelin
amide derivatives
compound
application
receptor antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201810560070.0A
Other languages
Chinese (zh)
Inventor
曾庆强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201810560070.0A priority Critical patent/CN108658958A/en
Publication of CN108658958A publication Critical patent/CN108658958A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a kind of amide derivatives formula I and its as the application of endothelin-receptor antagonists,Wherein：R1、R2、R3、R4It is independently selected from H, F or CH3.It finds that amide derivatives formula I of the present invention has preferable endothelin receptor antagonizing activity in the contraction experiment for inhibiting Endothelin to induce isolated rabbit aortic annulus, can be used to prepare that treat cardiovascular and cerebrovascular, hypertension, pulmonary hypertension, myocardial infarction, tumour, diabetic complication, nephrosis, asthma and thyroid gland hyperfunction etc. as endothelin-receptor antagonists.

Description

A kind of amide derivatives and its application as endothelin-receptor antagonists
Technical field
The invention belongs to chemical medicine, it is related to a kind of amide derivatives formula I and its as endothelin receptor antagonism The application of agent.
Background technology
Cardiovascular and cerebrovascular disease (cardiovascular and cerebrovascular diseases, CCVd) is heart The general designation of blood vessel and cranial vascular disease refers to hyperlipidemia, blood is sticky, caused by atherosclerosis, hypertension etc. Heart, brain and the body tissue ischemic or hemorrhagic disease that occur.The death rate of cardiovascular and cerebrovascular disease occupies various diseases First of, the final cause of the death overwhelming majority is myocardial hypertrophy, heart failure, cerebral apoplexy and fatal arrhythmia.Especially in recent years The case fatality rate of serious heart failure is high, has formed a problem of international the world of medicine.These diseases lack effective at present Medicine.
Endothelin (endothelin, ET) be made of 21 amino acid discoveries such as Yanagisawa within 1988 it is more Peptide is synthesized and is secreted by vascular endothelial cell, cardiac muscle, smooth muscle etc., belongs to sarafotoxin (sarafotoxin) family, has Powerful contracting blood vessel and rush vascular smooth muscle cells, is a kind of endogenous damage factor, in many hearts, brain, lung, kidney It is all of great significance in the morbidity of vascular diseases.ET has the shaped body of 3 kinds of forms, is referred to as ET-1, ET-2 and E-3, ET is acted on through Endothelin-converting Enzyme (ECEs) and activate, the ET of activation and its receptor in conjunction with and play a role, wherein ET1 is existing by force Strong and lasting vasoconstrictor effects, and be the inflammatory for causing a variety of diseases with cell growth and mitosis characteristic is promoted The factor.Due to the potential therapeutic value that endothelin antagonist is contained, major drugmaker of the world all energetically puts into endothelium In the research and development of plain antagonist, the research of endothelin antagonist has become hot spot.The stronger peptides of effect having found ET antagonists have BQ123, BQ160, FR2139317 etc., but are limited since the oral bioavailability rate of peptide agonist is low Its application in the angiocardiopathy of palpus long-term administration.Many drugmakers are dedicated to the non-peptides ET antagonisms for having Orally active The research of agent.The endothelin-receptor antagonists listed have Bosentan, tezosentan, enrasentan, sitaxentan, A Qusheng Smooth and ambrisentan, in treatment hypertension, pulmonary hypertension, tumour, diabetic complication, myocardial infarction and cerebral angiospasm etc. Aspect obtains very good effect.
Used in test example of the present invention control drug Bosentan chemical structural formula for：
Invention content
The invention discloses a kind of amide derivatives formula I, structure is：
Wherein：R1、R2、R3、R4It is independently selected from H, F or CH3.The invention further relates to the medicines of the amide derivatives formula I Acceptable salt or solvate on.
Further, amide derivatives formula I described in some preferred schemes is
The synthetic route that another object of the present invention discloses the amide derivatives formula I is：
Specifically synthetic method is：
1) 3- sulfamoyls propionic acid (compound 1) occurs into the presence of a base with 2,4- dihydroxy-benzoic acids (compound 2) Ring reacts, and generates (7- hydroxyl -2- oxo -2H- chromene -3- bases) Methanesulfomide (compound 3)；
2) in a suitable solvent, compound 3 reacts with iodomethane, generates (7- methoxyl group -2- oxo -2H- colors Alkene -3- bases) Methanesulfomide (compound 4)；
3) in a suitable solvent, compound 4 and iodide react generation (7- methoxyl groups -2,2- dimethyl - 2H- chromene -3- bases) Methanesulfomide (compound 5)；
4) compound 5 again with hexichol [b, d] thiophene reaction generate (4- (hexichol [b, d] thiene-3-yl) methoxyl group-2-7-, 2- lutidines -3- bases) Methanesulfomide (compound 6)；
5) in a suitable solvent, compound 6 and corresponding acyl chloride reaction, generate corresponding amide product.
Further, the alkali of the use in the step 1) can use potassium carbonate, and cesium carbonate, triethylamine, sodium hydroxide is molten Liquid or potassium hydroxide solution, sodium carbonate liquor, preferably triethylamine.
Further, the solvent in the step 2) can use n,N-Dimethylformamide (DMF), Dioxane, DMSO, DMF, acetone etc., preferably acetone；
Further, the solvent in the step 3) can use n,N-Dimethylformamide (DMF), Dioxane, DMSO, DMF, THF, acetone etc., preferably THF.
Further, solvent can be absolute ethyl alcohol, second eyeball, benzene, toluene, dimethylbenzene, ether, diformazan in the step 5) Base sulfoxide, n,N-Dimethylformamide (DMF), acetone, pyridine etc., preferably absolute ethyl alcohol.
Another object of the present invention discloses application of the amide derivatives formula I as endothelin-receptor antagonists. With the relevant disease of endothelin-receptor antagonists such as cardiovascular and cerebrovascular, hypertension, pulmonary hypertension, myocardial infarction, tumour, diabetes Complication, nephrosis, asthma and thyroid gland are hyperfunction etc..
Pharmaceutically acceptable salt of the present invention refers to the organic salt and inorganic salts of the compounds of this invention.Pharmaceutically may be used The salt that the nontoxic acid received is formed includes, but is not limited to, inorganic acid salt, such as hydrochloride, hydrobromate, phosphate, sulfuric acid Salt, perchlorate；Acylate, such as acetate, oxalates, maleate, tartrate, citrate, succinate, the third two Hydrochlorate；Or these salt are obtained by other methods described in the books or literature such as ion-exchange.Other can pharmaceutically connect The salt received includes adipate, alginates, ascorbate, aspartate, benzene sulfonate, benzoate, bisulphate, Borate, butyrate, camphor hydrochlorate, camsilate, cyclopentyl propionate, digluconate, lauryl sulfate, second Sulfonate, formates, fumarate, gluceptate, glycerophosphate, gluconate, Hemisulphate, enanthate, Caproate, hydriodate, 2- hydroxy-ethanesulfonate salts, lactobionate, lactate, laruate, lauryl sulfate, apple Hydrochlorate, mesylate, 2- naphthalene sulfonates, nicotinate, nitrate, oleate, palmitate, pamoate, pectate, persulfuric acid Salt, 3- phenylpropionic acid salt, picrate, pivalate, propionate, stearate, rhodanate, tosilate, 11 Hydrochlorate, valerate, etc..By including alkali metal, alkaline-earth metal, ammonium and N+ (C1-4 alkane with alkali appropriate salt obtained by the reaction Base) 4 salt.Water-soluble or oil-soluble or dispersion product can be obtained by quaternization.Can with the alkali metal of forming salt or Alkaline-earth metal includes sodium, lithium, potassium, calcium, magnesium, etc..Pharmaceutically acceptable salt further comprises appropriate, nontoxic ammonium, season The amine cation that ammonium salt and gegenions are formed, such as halide, hydroxide, carboxylate, hydrosulphate, phosphoric acid compound, nitre Acidulants, C1-8 azochlorosulfonate acid compounds and aromatic sulphonic acid compound.
Solvate of the present invention refers to that one or more solvent molecules are formed by with the compound of the present invention and form Close object.The solvent for forming solvate includes, but is not limited to, water, isopropanol, ethyl alcohol, methanol, dimethyl sulfoxide, ethyl acetate, Acetic acid and ethylaminoethanol.
Specific implementation mode
Embodiment 1：N- (((4- (hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) first Base) sulfonyl)-quinoline-2-formamide synthesis
The synthesis of 1-1, (7- hydroxyl -2- oxo -2H- chromene -3- bases) Methanesulfomide
By 3- sulfamoyls propionic acid (compound 1) (15.0g, 97.94mmol) and 2,4- dihydroxy-benzoic acids (compound 2) (10.2g, 66.18mmol) is dissolved in acetic anhydride (22.6mL), the careful addition triethylamine (13.2mL) into mixture, and Mixture is heated 4 hours.After having reacted, cooling is simultaneously diluted with water.The product of precipitation is filtered and is washed with methanol aqueous solution, Obtain (7- hydroxyl -2- oxo -2H- chromene -3- bases) Methanesulfomide (compound 3), 21.2g, yield 85%.1H-NMR (400MHz,CDCl3)δ:4.08(s,2H),5.14(s,2H),5.26(s,1H),6.74(s,1H),6.81(d,1H),7.51 (dd,1H),7.60(s,1H).13C-NMR(125MHz,CDCl3)δ:63.62,102.58,112.85,114.47,119.70, 129.31,140.10,156.42,157.32,160.10.LC-MS(ESI,pos,ion)m/z:256[M+H].
The synthesis of 1-2, (7- methoxyl group -2- oxo -2H- chromene -3- bases) Methanesulfomide
At room temperature, in the presence of Anhydrous potassium carbonate (6.3g, 45.58mmol), with being dissolved in acetone (50.0mL) Methyl iodide (4.0mL) solution and compound 3 (21.2g, 83.06mmol) are reacted one hour, and concentrated solvent is beaten with water, filtering, Obtain (7- methoxyl group -2- oxo -2H- chromene -3- bases) Methanesulfomide (compound 4), 12.0g, yield 98%.1H-NMR (400MHz,CDCl3)δ:3.84(s,3H),4.08(s,2H),5.87(s,2H),7.01(dd,1H),7.04(s,1H),7.58 (s,1H),7.68(dd,1H).13C-NMR(125MHz,CDCl3)δ:56.08,63.62,101.23,112.76,113.78, 119.70,128.73,140.10,156.59,157.32,162.49.LC-MS(ESI,pos,ion)m/z:270[M+H].
The synthesis of 1-3, (7- methoxyl group -2,2- dimethyl -2H- chromene -3- bases) Methanesulfomide
Using THF as solvent, compound 4 (12.0g, 44.56mmol) is made to occur with iodide (13g, 78.20mmol) Reaction flows back 4 hours, and after the completion of reaction, reaction, concentrated solvent, flash column chromatography separation, you can obtain yellow is quenched in acid adding Solid (7- methoxyl group -2,2- dimethyl -2H- chromene -3- bases) Methanesulfomide (compound 5), 10.5g, yield 83%.1H-NMR(400MHz,CDCl3)δ:1.45(s,6H),3.84(s,3H),4.08(s,2H),4.29(s,2H),6.43(s,1H), 6.65(dd,1H),7.18(s,1H),7.91(dd,2H).13C-NMR(125MHz,CDCl3)δ:27.07,56.08,62.25, 74.02,103.68,105.06,113.29,119.81,124.15,128.02,155.91,161.96.LC-MS(ESI,pos, ion)m/z:284[M+H].
The conjunction of 1-4, (4- (hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) Methanesulfomide At
Compound 5 (10.5g, 37.06mmol) is dissolved in anhydrous dichloroethylene (10mL), and is stirred continuously, at 5 DEG C Under, anhydrous Aluminum chloride (15.0g, 112.5mmol) is added into the solution of above-mentioned stirring, after stirring 0.5 hour, hexichol is added [b, d] thiophene (182.3mmol) simultaneously stirs mixture 12 hours at 50-60 DEG C.It is then added into ice and concentrated hydrochloric acid In the mixture of (13mL) to quench the reaction.It is extracted again by organic layer separation and by water layer with dichloromethane (2*25mL).It will close And extract washed with sodium bicarbonate (50mL), dried with anhydrous sodium sulfate, filter and evaporate.Obtained crude on silica gel Chromatography obtains thick liquid (4- (hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) Methanesulfomide (compound 6), 14.21g, yield 82%.1H-NMR(400MHz,CDCl3)δ:1.36(s,6H),3.21(dd,1H),3.46 (dd,1H),3.59(dt,1H),3.84(s,5H),4.51(d,1H),6.53-6.57(m,2H),7.24-7.31(m,3H), 7.56(td,1H),7.77(d,1H),7.86(dd,1H),8.03(d,1H),8.45(dd,1H).13C-NMR(125MHz, CDCl3)δ:25.75,47.5,50.49,53.73,56.08,77.15,103.64,105.65,117.38,119.13, 123.45,124.32,124.34,124.54,127.02,127.42,128.3,133.41,134.51,138.41,139.2, 140.4,154.65,161.83.LC-MS(ESI,pos,ion)m/z:468[M+H].
1-5, N- (((4- (hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) methyl) sulphur Acyl group)-quinoline-2-formamide synthesis
Compound 6 (14.04g, 30.02mmol) is added in absolute ethyl alcohol (150mL), quinoline-is then gradually added into 2- formyl chlorides (35mmol), stirring are warming up to reaction reflux.It reacts and finishes after about 8 hours, TLC monitors reaction end.It will reaction It after liquid stands cooling, filters, a small amount of absolute ethyl alcohol washing filter cake is used in combination, obtains white solid product N- (((4- (hexichol [b, d] Thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) methyl) sulfonyl) quinoline-2-formamide, 17.01g, yield 91%.1H-NMR(400MHz,CDCl3)δ:1.32(s,6H),3.21(dd,1H),3.46(dd,1H),3.63(td,1H),3.84 (s,3H),4.51(d,1H),6.53-6.57(m,2H),7.24-7.31(m,3H),7.56-7.62(m,3H),7.73-7.90 (m,5H),8.20(dd,1H),8.28(d,1H),8.45(dd,1H),8.59(dd,1H).13C-NMR(125MHz,CDCl3)δ: 25.75,47.5,52.81,54.09,56.08,77.15,103.64,105.65,117.38,118.55,119.13,123.45, 124.32,124.34,124.54,127.02,127.4,127.42,127.61,127.87,128.3,129.56,130.61, 133.41,134.51,137.46,138.41,139.2,140.4,141.05,153.85,154.65,157.93, 161.83.LC-MS(ESI,pos,ion)m/z:623[M+H]。
Embodiment 2：N- (((4- (hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) first Base) sulfonyl)-(the fluoro- quinoline of 4-) -5- formamides synthesis
Compound 6 (14.04g, 30.02mmol) is added in absolute ethyl alcohol (150mL), is then gradually added into that (4- is fluoro- Quinoline) -5- formyl chlorides (35mmol), stirring, which is warming up to, reacts reflux.It reacts and finishes after about 8 hours, TLC monitors reaction end. It after reaction solution is stood cooling, filters, a small amount of absolute ethyl alcohol washing filter cake is used in combination, obtains white solid product N- (((4- (hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) methyl) sulfonyl)-(the fluoro- quinoline of 4-) -5- formyls Amine, 17.89g, yield 93%.LC-MS(ESI,pos,ion)m/z:641[M+H].
Embodiment 3：N- (((4- (hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) first Base) sulfonyl)-(4- Methyl-quinolines) -5- formamides synthesis
Compound 6 (14.04g, 30.02mmol) is added in absolute ethyl alcohol (150mL), (4- first is then gradually added into Yl-quinoline) -5- formyl chlorides (35mmol), stirring, which is warming up to, reacts reflux.It reacts and finishes after about 8 hours, TLC monitorings reaction is eventually Point.It after reaction solution is stood cooling, filters, a small amount of absolute ethyl alcohol washing filter cake is used in combination, obtains white solid product N- (((4- (hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) methyl) sulfonyl)-(4- Methyl-quinolines) - 5- formamides, 17.39g, yield 91%.LC-MS(ESI,pos,ion)m/z:637[M+H].
Embodiment 4：N- (((4- (hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) first Base) sulfonyl)-(4,5- difluoro-quinolins) -5- formamides synthesis
Compound 6 (14.04g, 30.02mmol) is added in absolute ethyl alcohol (150mL), is then gradually added into (4,5- Difluoro-quinolin) -5- formyl chloride 35mmol), stirring is warming up to reaction reflux.It reacts and finishes after about 8 hours, TLC monitorings reaction is eventually Point.It after reaction solution is stood cooling, filters, a small amount of absolute ethyl alcohol washing filter cake is used in combination, obtains white solid product N- (((4- (hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) methyl) sulfonyl)-(bis- fluoro- quinolines of 4,5- Quinoline) -5- formamides, 18.598g, yield 94%.LC-MS(ESI,pos,ion)m/z:659[M+H].
Test example 1：Inhibit the contraction of Endothelin induction isolated rabbit aortic annulus
Normal rabbits auricular vein pneumatic needl opens chest after putting to death, take out aorta pectoralis, separation.It is placed in 4 containing saturated oxygen Connective tissue is removed in DEG C cold K-H liquid.Gently rubbed removal endarterium epithelial cell with cotton thread.It is cut into the vascular circle of 4-6mm, It hangs in the 8mL baths containing K-H buffer salt solutions, leads to pure O2, pH7.4,37 DEG C of constant temperature.Adjusting rest tension is 2g, balance 60min。
ET-1 (10 is added-8Mol/L final concentrations), 40min is incubated when vessel retraction reaches maximum tension, administration group difference Test-compound (10 is added-6Mol/L final concentrations), if solvent group is control.Observe its vessel retraction to Endothelin in 40min The antagonism of reaction.The calculating of endothelin antagonist inhibiting rate：ET-1 to vessel retraction 40min when tension be A (g), Test-compound (10-6Mol/L final concentrations) be incubated 40min after vessel retraction tension be B (g), then its inhibit percentage be (A- B)/A × 100%.(N=6)
Table 1ERA induces rabbit myocardium vessel tension variation to ET-1
Amide derivatives formula I of the present invention has preferable endothelin receptor antagonizing activity, can be used as Endothelin Receptor antagonist be used to prepare treatment cardiovascular and cerebrovascular, hypertension, pulmonary hypertension, myocardial infarction, tumour, diabetic complication, Nephrosis, asthma and thyroid gland are hyperfunction etc..

Claims (5)

1. a kind of general formula structure is the amide derivatives and its pharmaceutically acceptable salt or solvate of formula I
Wherein：R1、R2、R3、R4It is independently selected from H, F or CH3。
2. amide derivatives formula I as described in claim 1, characterized in that be selected from following compound：
3. application of the amide derivatives formula I as claimed in claim 1 or 2 as endothelin-receptor antagonists.
4. application of the amide derivatives formula I as claimed in claim 1 or 2 in the drug for preparing cardiovascular and cerebrovascular disease.
5. amide derivatives formula I as claimed in claim 1 or 2 is preparing cardiovascular and cerebrovascular, hypertension, pulmonary hypertension, the heart Application in the hyperfunction drug of flesh infarct, tumour, diabetic complication, nephrosis, asthma, thyroid gland.
CN201810560070.0A 2018-06-03 2018-06-03 A kind of amide derivatives and its application as endothelin-receptor antagonists Withdrawn CN108658958A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810560070.0A CN108658958A (en) 2018-06-03 2018-06-03 A kind of amide derivatives and its application as endothelin-receptor antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810560070.0A CN108658958A (en) 2018-06-03 2018-06-03 A kind of amide derivatives and its application as endothelin-receptor antagonists

Publications (1)

Publication Number Publication Date
CN108658958A true CN108658958A (en) 2018-10-16

Family

ID=63775274

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810560070.0A Withdrawn CN108658958A (en) 2018-06-03 2018-06-03 A kind of amide derivatives and its application as endothelin-receptor antagonists

Country Status (1)

Country Link
CN (1) CN108658958A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106687465A (en) * 2014-06-11 2017-05-17 维纳拓尔斯制药公司 Beta-lactamase inhibitors
CN107759652A (en) * 2017-08-30 2018-03-06 大连理工大学 Containing cholesteric coumarin derivatives and its synthesis and application

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106687465A (en) * 2014-06-11 2017-05-17 维纳拓尔斯制药公司 Beta-lactamase inhibitors
CN107759652A (en) * 2017-08-30 2018-03-06 大连理工大学 Containing cholesteric coumarin derivatives and its synthesis and application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FILIPE AREIAS 等: "New chromene scaffolds for adenosine A2A receptors: Synthesis, pharmacology and structureeactivity relationships", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *

Similar Documents

Publication Publication Date Title
KR102187608B1 (en) SSAO inhibitor
EP3632910B1 (en) 3,4-dihydroquinolinones as fxr receptor agonists
FI106857B (en) A process for the preparation of novel pharmacologically active salicylic acid derivatives
TW385306B (en) Method for producing crystals of benzimidazole derivatives
CN104245663B (en) bicyclic compound
CA2693552A1 (en) Pyridone compound
JP7434278B2 (en) Deuterated derivatives of ranifibranol
JPH02138262A (en) Novel medically-active 1,2,3,4,4a,5,10,10a- octahydro-benzo(g)quinoline derivative
CN111440145A (en) Novel crystal form of high-purity trelagliptin and preparation method thereof
JP2007261945A (en) Thiazole derivative
US6610718B2 (en) Processes for making- and a new crystalline form of- leflunomide
CN108570055A (en) A kind of amide derivatives and its application in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension
CN108947989B (en) Deuterated optical isomer and medical application thereof
CN108658958A (en) A kind of amide derivatives and its application as endothelin-receptor antagonists
CN108586445A (en) Amide derivatives and its application as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension
CN108586472A (en) Amide derivatives and its application as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension
CN108570056A (en) A kind of amide derivatives and its application in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension
WO2017101881A1 (en) Ginkgolide b derivative and preparation method and use thereof
JPH07267954A (en) New 3-phenylsulfonyl-3,7-diazabicyclo(3,3,1)nonane compound,its production, and antiarrhythmic agent
NO744175L (en)
CN107722007B (en) Preparation method of apixaban impurity
JP3213576B2 (en) Substituted pyridine
NO752109L (en)
NO317993B1 (en) Benzoylguanidine Derivatives, Pharmaceutical Preparations, Methods for Preparing and Using Them in the Preparation of Medications
CN117229259B (en) 8-quinoline sulfonamide phenylimidazole compound and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20181016

WW01 Invention patent application withdrawn after publication